Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | RXRA | P19793 | 6/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 6/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 6/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19479367 | 0.81 | HPGD (0.47) | SIGMAR1LMNAMAPTADRA2CHTR2A | |
| SCHEMBL19484455 | 0.81 | HPGD (0.47) | SIGMAR1LMNAMAPTADRA2CHTR2A | |
| SCHEMBL19480874 | 0.79 | LMNA (0.41) | SIGMAR1LMNAMAPTADRA2CHTR2A | |
| SCHEMBL19480887 | 0.79 | LMNA (0.41) | SIGMAR1LMNAMAPTADRA2CHTR2A | |
| SCHEMBL21984718 | 0.75 | SIGMAR1 (0.42) | SIGMAR1LMNAMAPTADRA2CHTR2A | |
| SCHEMBL20909018 | 0.75 | SIGMAR1 (0.42) | SIGMAR1LMNAMAPTADRA2CHTR2A | |
| SCHEMBL19477233 | 0.75 | SIGMAR1 (0.42) | SIGMAR1LMNAMAPTADRA2CHTR2A | |
| Hydrochloric Acid SCHEMBL28378834 | 0.74 | SIGMAR1 (0.41) | SIGMAR1LMNAMAPTADRA2CHTR2A | |
| Hydrochloric Acid SCHEMBL28378836 | 0.74 | SIGMAR1 (0.41) | SIGMAR1LMNAMAPTADRA2CHTR2A | |
| SCHEMBL10264523 | 0.74 | HPGD (0.46) | RXRAGRIN1GRIN2BPOLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3442965-B1 | NOVEL N-[(HETEROARYLOXY)PROPANYL]HETEROARYL CARBOXAMIDES | BOEHRINGER INGELHEIM INT (DE) | 2021-05-26 | — | — | EP | disclosed |
| US-10738031-B2 | N-[(heteroaryloxy)propanyl]heteroaryl carboxamides as antagonists of orexin subtype 1 receptor activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-08-11 | — | — | US | disclosed |
| EP-3442967-B1 | NOVEL N-[(PYRIMIDINYLOXY)PROPANYL]BENZAMIDES | BOEHRINGER INGELHEIM INT (DE) | 2020-05-13 | — | — | EP | disclosed |
| US-10392369-B2 | N-[(pyrimidinyloxy)propanyl]benzamides | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-08-27 | — | — | US | disclosed |
| US-20190112292-A1 | NOVEL N-[(HETEROARYLOXY)PROPANYL]HETEROARYL CARBOXAMIDES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-04-18 | — | — | US | disclosed |
| US-20190112295-A1 | NOVEL N-[(PYRIMIDINYLOXY)PROPANYL]BENZAMIDES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-04-18 | — | — | US | disclosed |
| WO-2017178338-A1 | NOVEL N-[(PYRIMIDINYLOXY)PROPANYL]BENZAMIDES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-10-19 | — | — | WO | disclosed |
| WO-2017178344-A1 | NOVEL N-[(HETEROARYLOXY)PROPANYL]HETEROARYL CARBOXAMIDES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190112292-A1 | NOVEL N-[(HETEROARYLOXY)PROPANYL]HETEROARYL CARBOXAMIDES | HCRTR2, HCRTR1, CNR2 | SIGMAR1 134/4885LMNA 3095/4885MAPT 1608/4885 |
| US-10392369-B2 | N-[(pyrimidinyloxy)propanyl]benzamides | HCRTR1, HCRTR2, CNR1 | SIGMAR1 91/4885LMNA 2187/4885MAPT 1607/4885 |
| US-10738031-B2 | N-[(heteroaryloxy)propanyl]heteroaryl carboxamides as antagonists of orexin subtype 1 receptor activity | HCRTR2, HCRTR1, CNR1 | SIGMAR1 206/4885LMNA 2934/4885MAPT 2092/4885 |
| US-20190112295-A1 | NOVEL N-[(PYRIMIDINYLOXY)PROPANYL]BENZAMIDES | HCRTR1, HCRTR2, CNR1 | SIGMAR1 85/4885LMNA 2753/4885MAPT 1719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.